Novo Nordisk Says Mismatched Diabetes Drug Ads Triggered Lawsuit Vs. Lilly

Dow Jones07-21 20:23

Novo Nordisk's false advertising lawsuit against Eli Lilly extends to diabetes treatments. The company alleges Lilly's Mounjaro ads compare its highest 15 mg dose against a one mg dose of Ozempic, even though the FDA approved a more effective two mg maintenance dose of Ozempic more than four years ago. Novo Nordisk says Lilly intentionally selected outdated studies to create a misleading impression of superiority. The company sent a cease-and-desist request before filing, but says Lilly refused to pull or meaningfully correct the ads

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

July 21, 2026 08:23 ET (12:23 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment